文献速递精神分裂症与精神病性障碍

强啡肽与κ阿片受体在精神分裂症症状学中的作用:证据综述

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.
PubMed 文献 · Biol Psychiatry · 2019-05-22

本文综述了κ阿片系统(强啡肽与κ阿片受体)在精神分裂症阳性和阴性症状病理中的证据。健康志愿者中κ阿片受体激动剂可产生拟精神病效应,可被纳洛酮和纳曲酮逆转;4种泛阿片拮抗剂显示对精神分裂症有治疗获益。κ阿片受体与多巴胺通路相互作用,组织学证据提示精神分裂症中κ阿片受体信号异常。

要点

  • κ阿片受体激动剂在健康志愿者中产生拟精神病效应,可被纳洛酮/纳曲酮逆转。
  • 4种泛阿片拮抗剂显示对精神分裂症有治疗获益。
  • 组织学证据提示精神分裂症中κ阿片受体信号异常,与多巴胺通路交互。

核心结论

  • κ阿片系统(强啡肽/κ阿片受体)参与精神分裂症阳性和阴性症状的病理,并具有治疗潜力。

研究设计与样本

  • 本文为叙述性综述,汇总临床研究证据,未报告系统检索策略或样本量。

主要发现

  • 健康志愿者中κ阿片受体激动剂产生拟精神病效应,可被纳洛酮和纳曲酮逆转。
  • 4种泛阿片拮抗剂显示对精神分裂症有治疗获益。
  • κ阿片受体与精神分裂症中受损的多巴胺通路存在交互作用。
  • 组织学证据提示精神分裂症中κ阿片受体信号异常。

临床怎么用

  • κ阿片系统可作为精神分裂症新药研发的潜在靶点,泛阿片拮抗剂可能带来治疗获益。

局限性

  • 本文为综述,未报告系统检索策略、纳入标准或偏倚评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia is a debilitating mental illness that affects approximately 1% of the world's population. Despite much research in its neurobiology to aid in developing new treatments, little progress has been made. One system that has not received adequate attention is the kappa opioid system and its potential role in the emergence of symptoms, as well as its therapeutic potential. Here we present an overview of the kappa system and review various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the positive and negative symptoms of schizophrenia. This overview includes evidence for the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and their reversal by the pan-opioid antagonists naloxone and naltrexone and evidence for a therapeutic benefit in schizophrenia for 4 pan-opioid antagonists. We describe the interactions between kappa opioid receptors and the dopaminergic pathways that are disrupted in schizophrenia and the histologic evidence suggesting abnormal kappa opioid receptor signaling in schizophrenia. We conclude by discussing future directions.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Clark SD, Abi-Dargham A. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. Biol Psychiatry. 2019. PMID: 31376930. doi:10.1016/j.biopsych.2019.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。